Literature DB >> 21153864

Identification and analysis of function of a novel splicing variant of mouse receptor activator of NF-κB.

Satomi Mukai1, Riko Kitazawa, Junko Ishii, Takeshi Kondo, Akihiro Hakozaki, Keisuke Horiuchi, Ryuma Haraguch, Kiyoshi Mori, Sohei Kitazawa.   

Abstract

Receptor activator of NF-κB (RANK) is a member of the tumor necrosis factor receptor (TNFR) family expressed in osteoclast precursors, and RANK-RANK ligand (RANKL) signaling is a key system for differentiation, activation and survival of osteoclasts. Here, we report the identification of a novel alternative splicing variant of mouse RANK gene (vRANK) that contains a new intervening exon between exon 1 and exon 2 of mouse full-length RANK (fRANK) mRNA. Since this novel exon contains the stop codon, vRANK encodes truncated amino acids that have a portion of the signal peptide of fRANK and an additional 19 amino acids that show no homology to previously reported domains. By transient transfection studies with vRANK-GFP and -Flag expressing constructs, vRANK was found localized mostly in the cytoplasm and partly in the cell membrane, but was not secreted into the culture supernatant. Under the stimulation of various factors, the expression of vRANK mRNA was almost parallel to that of fRANK in RAW264.7 cells not treated with M-CSF. Overexpression of vRANK, on the other hand, decreased TRACP (a marker of osteoclasts) mRNA expression as well as the number of TRACP-positive multinucleated giant cells. While the mRNA expression levels of NFATc1 (a master transcriptional factor of the osteoclast differentiation program) were not affected, apoptotic cells increased significantly in vRAN K-transfected cells treated with sRANKL. Taken together, these results suggest that vRANK is a novel osteoclast suppressor that reduces the number of RANKL-induced mature osteoclasts mainly by negating the anti-apoptotic effect of RANKL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21153864     DOI: 10.1007/s11010-010-0679-z

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  29 in total

Review 1.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

2.  The InterPro Database, 2003 brings increased coverage and new features.

Authors:  Nicola J Mulder; Rolf Apweiler; Teresa K Attwood; Amos Bairoch; Daniel Barrell; Alex Bateman; David Binns; Margaret Biswas; Paul Bradley; Peer Bork; Phillip Bucher; Richard R Copley; Emmanuel Courcelle; Ujjwal Das; Richard Durbin; Laurent Falquet; Wolfgang Fleischmann; Sam Griffiths-Jones; Daniel Haft; Nicola Harte; Nicolas Hulo; Daniel Kahn; Alexander Kanapin; Maria Krestyaninova; Rodrigo Lopez; Ivica Letunic; David Lonsdale; Ville Silventoinen; Sandra E Orchard; Marco Pagni; David Peyruc; Chris P Ponting; Jeremy D Selengut; Florence Servant; Christian J A Sigrist; Robert Vaughan; Evgueni M Zdobnov
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

3.  SOSUI: classification and secondary structure prediction system for membrane proteins.

Authors:  T Hirokawa; S Boon-Chieng; S Mitaku
Journal:  Bioinformatics       Date:  1998       Impact factor: 6.937

4.  Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Authors:  D L Lacey; E Timms; H L Tan; M J Kelley; C R Dunstan; T Burgess; R Elliott; A Colombero; G Elliott; S Scully; H Hsu; J Sullivan; N Hawkins; E Davy; C Capparelli; A Eli; Y X Qian; S Kaufman; I Sarosi; V Shalhoub; G Senaldi; J Guo; J Delaney; W J Boyle
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

5.  Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin E2.

Authors:  H Kaji; T Sugimoto; M Kanatani; K Nishiyama; K Chihara
Journal:  J Bone Miner Res       Date:  1997-05       Impact factor: 6.741

6.  Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression.

Authors:  Morten A Karsdal; Pernille Hjorth; Kim Henriksen; Tove Kirkegaard; Karina L Nielsen; Henriette Lou; Jean-Marie Delaissé; Niels T Foged
Journal:  J Biol Chem       Date:  2003-08-20       Impact factor: 5.157

7.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

Authors:  D M Anderson; E Maraskovsky; W L Billingsley; W C Dougall; M E Tometsko; E R Roux; M C Teepe; R F DuBose; D Cosman; L Galibert
Journal:  Nature       Date:  1997-11-13       Impact factor: 49.962

8.  Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1.

Authors:  Masahito Matsumoto; Masakazu Kogawa; Seiki Wada; Hiroshi Takayanagi; Masafumi Tsujimoto; Shigehiro Katayama; Koji Hisatake; Yasuhisa Nogi
Journal:  J Biol Chem       Date:  2004-08-09       Impact factor: 5.157

9.  Interleukin-4 induces expression of the integrin alpha v beta 3 via transactivation of the beta 3 gene.

Authors:  S Kitazawa; F P Ross; K McHugh; S L Teitelbaum
Journal:  J Biol Chem       Date:  1995-02-24       Impact factor: 5.157

10.  Lipopolysaccharide suppresses RANK gene expression in macrophages by down-regulating PU.1 and MITF.

Authors:  Junko Ishii; Riko Kitazawa; Kiyoshi Mori; Kevin P McHugh; Eiichi Morii; Takeshi Kondo; Sohei Kitazawa
Journal:  J Cell Biochem       Date:  2008-10-15       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.